Wirsching, H., Schrimpf, D., Capper, D., Jones, D. T. W., Pfister, S., & Deimling, A. v. (2020). Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: The randomized, open-label, phase II ARTE trial. Annals of oncology, 29(6), . https://doi.org/10.1093/annonc/mdy120
Chicago-Zitierstil (17. Ausg.)Wirsching, Hans-Georg, Daniel Schrimpf, David Capper, David T. W. Jones, Stefan Pfister, und Andreas von Deimling. "Bevacizumab Plus Hypofractionated Radiotherapy Versus Radiotherapy Alone in Elderly Patients with Glioblastoma: The Randomized, Open-label, Phase II ARTE Trial." Annals of Oncology 29, no. 6 (2020). https://doi.org/10.1093/annonc/mdy120.
MLA-Zitierstil (9. Ausg.)Wirsching, Hans-Georg, et al. "Bevacizumab Plus Hypofractionated Radiotherapy Versus Radiotherapy Alone in Elderly Patients with Glioblastoma: The Randomized, Open-label, Phase II ARTE Trial." Annals of Oncology, vol. 29, no. 6, 2020, https://doi.org/10.1093/annonc/mdy120.